Nelson Vergel
Founder, ExcelMale.com
LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products.
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T"). Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion of the SOAR clinical study by mid-year as well as file the New Drug Application ("NDA") with the U.S. Food and Drug Administration in the second half of this year.
http://www.fiercedrugdelivery.com/p...pcn-1021-oral-testosterone-phase-3-clinical-0
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T"). Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion of the SOAR clinical study by mid-year as well as file the New Drug Application ("NDA") with the U.S. Food and Drug Administration in the second half of this year.
http://www.fiercedrugdelivery.com/p...pcn-1021-oral-testosterone-phase-3-clinical-0
